不同剂量阿托伐他汀对高脂血症患者高敏C反应蛋白及颈动脉内膜中层厚度的影响

目的观察强化降脂对高脂血症患者高敏C反应蛋白和颈动脉内膜中层厚度（CIMT）的影响。方法164例高血脂症患者随机分为常规治疗组79例，强化降脂组85例，分别予阿托伐他汀10mg·d^-1或40mg·d^-1。于用药前及用药6个月后测定总胆固醇（TC），低密度脂蛋白胆固醇（LDL—C），高密度脂蛋白胆固醇（HDL—C），甘油三酯（TG）。观察高敏C反应蛋白（hs—CRP）及CIMT的变化。结果强化降脂组，hs-CRP由用药前（5．14±0．96）mg·L^-1，降至用药6个月时的（1．58±0．25）mg·L^-1（P〈0．05），较常规治疗组（5．16±0．98）mg·L^-1降至（2．68±0．5）mg·L^-1有更显著的疗效。强化降脂组CIMT由用药前（1．54±0．17）mm，降至用药6个月时的（1．41±0．21）mm（P〈0．05），较常规治疗组（1．54±0．16）mm降至（1．51±0．17）mm有显著的效果。结论强化降脂治疗能更有效地降低高敏C反应蛋白（hs—CRP），降低CIMT。

Different Doses of Atorvastatin on Hyperlipidemia in Patients with High-Sensitivity C-Reactive Protein and Carotid Artery Intima-media Thickness

OBJECTIVE To investigate the effect of intensive lipid-lowering hyperlipidemia in patients with high-sensitivity c-reactive protein and carotid artery intima-media thickness (CIMT). METHODS 164 cases of hyperlipidemia were randomly divided into conventional treatment group 79 cases, 85 cases of intensive lipid-lowering group, were to atorvastatin 10 mg·d^-1 or 40 mg·d^-1. In the former drug use and 6 months after the determination of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG). Observe high sensitive C-reactive protein (hs-CRP) and CIMT. RESULTS The outcome of intensive lipid-lowering group, hs-CRP by the former administration (5.14±0.96)mg·L^-1, drug use fell to 6 months at the time of (1.58±0.25)mg·L^-1(P<0.05), than conventional treatment group (5.16±0.98)mg·L^-1 reduced (2.68±0.5)mg·L^-1 have a more significant effect. CIMT group of intensive lipid-lowering drugs by the former (1.54±0.17)mm, drug use fell to 6 months at the time of (1.41±0.21)mm (P<0.05), than the conventional treatment group (1.54±0.16)mm to (1.51±0.17)mm significant results. CONCLUSION Intensive lipid-lowering therapy method is more effective in reducing high-sensitivity C-reactive protein (hs-CRP), reducing CIMT.